Upadacitinib monotherapy improved symptoms and quality of life (QoL) in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the phase III Measure Up 1 and 2 studies presented at EADV 2020.
Treatment with low-dose (LD) or high-dose (HD) secukinumab significantly improved Psoriasis Area and Severity Index (PASI)* scores in paediatric patients with severe chronic plaque psoriasis, according to a study presented at EADV 2020.
A topical gel treatment derived from birch bark significantly speeds up wound healing compared with standard care in patients with epidermolysis bullosa (EB) lesions, according to the EASE trial presented at the EADV 2020 Conference — representing the first-ever treatment to show positive results for the rare skin disorder.
Treatment with apremilast led to significantly improvedpatient-reported quality of life (QoL) outcomes in patients with moderate-to-severe plaque psoriasis of the scalp, according to the STYLE* study presented at EADV 2020.
The efficacy of tildrakizumab in chronic moderate-to-severe* plaque psoriasis is maintained after 5 years of treatment, final pooled analyses of the phase III reSURFACE 1 and reSURFACE 2 trials showed.
The modified glutathione (GSH-C4) with beta glycyrrhetic and azelaic acids cream is effective in the treatment of mild-to-moderate rosacea, with local tolerability consistent with other antirosacea medications, according to a study presented at the 29th Congress of the European Academy of Dermatology and Venereology (EADV 2020).
Levels of insulin resistance markers tend to be elevated in patients with acne vulgaris, supporting the association between acne vulgaris and insulin resistance, according to the results of a systematic review and meta-analysis.
INCB054707, an oral Janus kinase (JAK)1 inhibitor, shows promise in the treatment of moderate-to-severe hidradenitis suppurativa, reducing the abscess and inflammatory nodule count in addition to having an acceptable safety profile, according to data from two phase II trials.